4233v4 -> 2549 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475

Sundar R, Chenard-Poirier M, Collins DC, Yap TA

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Front Med (Lausanne) 4:39 (2017)
DOI:10.3389/fmed.2017.00039

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Cancer Discov 5:850-9 (2015)
DOI:10.1158/2159-8290.CD-15-0285

Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, Hong S, Jung HS, Oh E, Song JY, Lee MS, Kim M, Jung K, Kim J, Shin YK, Choi YL, Kim HR

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.

J Thorac Oncol 12:1233-1246 (2017)
DOI:10.1016/j.jtho.2017.04.031

Drilon A, Cappuzzo F, Ou SI, Camidge DR

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

J Thorac Oncol 12:15-26 (2017)
DOI:10.1016/j.jtho.2016.10.014

Organ SL, Tsao MS

An overview of the c-MET signaling pathway.

Ther Adv Med Oncol 3:S7-S19 (2011)
DOI:10.1177/1758834011422556